Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Cervical Cancer
Status:
Unknown status
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
Nimotuzumab is a humanized monoclonal antibody against epidermal growth factor receptor
(EGFR). Clinical trials are ongoing globally to evaluate Nimotuzumab in different
indications. Nimotuzumab has been approved to treat squamous cell carcinoma of head and neck
(SCCHN), glioma and nasopharyngeal carcinoma in different countries. The clinical phaseâ…¡trial
is designed to assess the resection rate and pathological complete response of nimotuzumab
plus carboplatin and paclitaxel in patients with cervical cancer.